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peared to be due to uncoupling of oxidative phosphorylation byfree 
fatty acids. By uncoupling myocardial oxidative phosphorylation, free 
fatty acids can cause oxygen to be consumed that is not linked to the 
generation of ATP. Also, free fatty acids can stimulate adenosine 
triphosphatase activity and increase ATP consumption that is not 
linked to cellular work; that is, ATP consumption ot used for basal 
metabolism or excitation-contraction c upling. 
Last, in addition to the effects of dichloroacetate on substrate use 
by the myocardium and the effects of substrate use on mechanical 
efficiency, dichloroacetate also stimulates alpha-ketoglutarate dehy- 
drogenase in cardiac muscle by dephosphorylation (3). Increased 
alpha-ketoglutarate d hydrogenase activity could lead to enhanced 
substrate level (TCA cycle) phosphorylation and thereby lead to 
additional ATP production. Although this is speculative, this is yet 
another potential mechanism by which dichloroacetate could improve 
mechanical efficiency above and beyond what would be expected 
simply from a change in P/O ratios of substrate. On the other hand, the 
sodium salt of dichloroacetate does not appear to have vasodilating 
properties. Although the di-isopropyl ammonium salt of dichloroac- 
etate (DIPA) is a vasodilator (4), the vasodilating properties of DIPA 
are probably due to the di-isopropyl ammonium salt of dichloroacetate 
and not due to the dichloroacetate moiety. The sodium salt of 
dichloroacetate has been studied recently in intact dogs, and the results 
from these investigations show little if any direct inotropic or vasodi- 
lating actions of dichloroacetate (R. Wilkins, personal communica- 
tion). The actions of dichloroacetate thus appear to be substantially 
metabolic. 
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The authors of this article have reported errors in some of the 
data in Table 2. The affected portion of the table with correct 
data is reproduced below. The authors regret the error. 
Table 2. ST Segment Resolution by Demographic, Clinical and Therapeutic Variables 
Decrease inTotal ST 
Segment Elevation ->50% 
Total No. No. of Odds 
of Pts Pts % Ratio 
HR (beats/min) 
<60 1,255 832 66.3 1 
60-100 5,712 3,820 66.9 1.03 
> 100 459 299 65.1 0.95 
Systolic BP (mm Hg) 
<100 386 260 67.4 1 
100-150 5,390 3,594 66.7 0.97 
>150 1,650 1,097 66.5 0.96 
Treatment 
SK 3,660 2,567 70.1 1 
t-PA 3,766 2,384 63.3 0.73 
Heparin 3,703 2,479 66.9 1 
No heparin 3,723 2,472 66.4 0.98 
95% Confidence 
Interval 
0.90-1.17 
0.76-1.19 
0.78 -1.21 
0.76 -1.22 
0.66-0.81 
0.89-1.07 
